ƽ

ѱ԰ܱ™ Osteogenic Differentiation Kit (Human)

For the in vitro differentiation of human MSCs into osteoblasts

ѱ԰ܱ™ Osteogenic Differentiation Kit (Human)

For the in vitro differentiation of human MSCs into osteoblasts

Catalog #
(Select a product)
For the in vitro differentiation of human MSCs into osteoblasts
Request Pricing Request Pricing

Product Advantages


  • Compatible with human MSCs previously culture-expanded in ѱ԰ܱ™ expansion media.

  • Available in an easy-to-use two-component format.

  • Rigorous raw material screening and quality control minimize lot-to-lot variability.

What's Included

  • ѱ԰ܱ™ Osteogenic Differentiation Basal Medium (Human), 200 mL
  • ѱ԰ܱ™ Osteogenic Differentiation 5X Supplement (Human), 50 mL

Overview

Induce efficient osteogenic differentiation of human mesenchymal stromal cells (MSCs) and (hPSC)-derived mesenchymal progenitors using the ѱ԰ܱ™ Osteogenic Differentiation Kit (Human). This kit drives robust mineralization and osteoblast marker expression across MSCs expanded in ѱ԰ܱ™ media, enabling reliable assessment of osteogenic potential in diverse MSC workflows.


Use this kit as part of a complete MSC functional assessment workflow. Pair with the ѱ԰ܱ™ Adipogenic Differentiation Kit (Human) and ѱ԰ܱ™-ACF Chondrogenic Differentiation Kit to evaluate trilineage differentiation potential and verify MSC identity and potency. These ready-to-use reagents enable reliable assessment of MSC identity and potency while ensuring reproducible lineage-specific outcomes across the complete ѱ԰ܱ™ workflow.
Cell Type
Mesenchymal Stem and Progenitor Cells, Osteoblasts
Application
Cell Culture, Differentiation
Brand
MesenCult
Area of Interest
Drug Discovery and Toxicity Testing, Stem Cell Biology

Data Figures

Figure 1. Robust Bone Marrow Mesenchymal Stem and Progenitor Cells (BM MSCs) Osteogenic Differentiation is Achieved in 14 days

Human BM MSCs were derived and expanded for 3 passages using the MesenCult™-ACF Culture Kit (Catalog #05449), MesenCult™ Proliferation Kit (Catalog #05411) or in MesenCult™-hPL Medium (05439). Once MSCs reach greater than 95% confluency, MesenCult™ Osteogenic medium was added to each MSC culture. Osteogenic differentiation was observed within 14 days of induction as indicated by strong alkaline phosphatase activity (red stain) and bone mineralization by the von Kossa method (black stain). Negative controls of undifferentiated MSC cultures were kept in each MesenCult™ MSC expansion media for the same time period. Negative Controls show little or no alkaline phosphatase activity and bone mineralization.

Figure 2. MesenCult™ Osteogenic Medium Leads to Faster and Stronger Osteogenic Differentiation When Compared to A Commercial Osteogenic Differentiation Medium

BM MSCs derived and expanded in MesenCult™-ACF or MesenCult™ Proliferation medium were differentiated for 14 days in either MesenCult™ Osteogenic or another Commercial Osteogenic Medium. Differentiation assays using the MesenCult™ Osteogenic medium displayed stronger alkaline phosphatase activity (red stain) and bone mineralization (black stain) when compared to cultures differentiated with a Commercial Osteogenic Medium.

Figure 3. Osteogenic Differentiation of ES-Derived Mesenchymal Progenitor Cells (MPCs)

Mesenchymal progenitor cells (MPCs) were derived from a human iPS or ES cell line using the STEMdiff™ Mesenchymal Progenitor Kit (Catalog #05240) and expanded for 18 or 17 passages, respectively. Cultures of iPS- and ES-derived MPCs were then differentiated for 20 or 27 days in MesenCult™ Osteogenic Differentiation Medium. Strong alkaline phosphatase activity (red stain) and bone mineralization (black stain) were observed at 20 days of osteogenic differentiation, which was further enhanced after 27 days of osteogenic differentiation.

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Document Type
Product Name
Catalog #
05465
Lot #
All
Language
English
Document Type
Product Name
Catalog #
05465
Lot #
All
Language
English
Document Type
Product Name
Catalog #
05465
Lot #
All
Language
English

Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Resources and Publications

Publications (12)

MRAP mediated adipocyte differentiation by thymic mesenchymal stromal cells contributes to thymic involution D. Wang et al. Nature Communications 2025 Nov

Abstract

Adipocyte deposition is believed to be a primary characteristic of age-related thymic involution, but the underlying cellular and molecular mechanisms remain unknown. We show here that thymic mesenchymal stromal cells (tMSCs) have a higher tendency to differentiate into adipocytes and melanocortin-2 receptor accessory protein (MRAP) is a potential driver of tMSCs adipogenesis. Furthermore, we discover that thymosin-α1 promotes MRAP expression in tMSCs through FoxO1 signaling pathway. Additionally, the proportion of tMSCs increase in older mice compared to young mice. Importantly, MRAP is also necessary for human thymic MSCs to differentiate into adipocytes when exposed to thymosin-α1. Single-cell RNA-seq analysis of human thymus revealed an accumulation of tMSCs and adipocytes during aging, indicating a strong potential for adipogenic differentiation in age-related thymic involution. Thus, we have revealed MRAP as a key factor in promoting thymic MSCs adipogenesis triggered by thymosin-α1 and FoxO1 pathway, which may serve as potential target to hinder adiposity in age-related thymic involution. Adipocyte deposition is believed to be a primary characteristic of age-related thymic involution. Here, the authors show that MRAP is a key factor in promoting thymic MSCs adipogenesis triggered by thymosin-α1 and FoxO1 pathway, which provide a new mechanism for age-related thymic involution
A scalable platform for EPSC-Induced MSC extracellular vesicles with therapeutic potential S. Gong et al. Stem Cell Research & Therapy 2025 Aug

Abstract

BackgroundExtracellular Vesicles (EVs) derived from mesenchymal stem cells (MSCs) have gained recognition as promising therapeutic and drug delivery agents in regenerative medicine. However, their clinical application is limited by donor variability, low scalability, and inconsistent therapeutic quality. To overcome these challenges, a robust and standardized production platform is urgently needed.MethodsWe developed a scalable biomanufacturing strategy by generating and expanding MSCs from extended pluripotent stem cells (EPSC) using a suspension bioreactor culture system. A fixed-bed bioreactor was integrated for automated, continuous expansion of iMSCs and downstream EV harvesting. EVs were isolated through a streamlined protocol and characterized for size, morphology, surface markers, and bioactivity. Therapeutic efficacy was assessed in a bleomycin-induced pulmonary fibrosis mouse model.ResultsiMSC-derived EVs (iMSC-EVs) exhibited comparable characteristics to primary MSC-EVs, including a size distribution of 70–80 nm, cup-shaped morphology, and expression of canonical EV markers (CD63, CD81, TSG101). iMSCs were expanded for up to 20 days in 3D culture, yielding > 5 × 10⁸ cells per batch using a suspension bioreactor culture system and producing ~ 1.2 × 10¹³ EV particles/day in a fixed-bed bioreactor. In vivo, iMSC-EVs significantly reduced Ashcroft fibrosis scores and bronchoalveolar lavage fluid protein levels in bleomycin-injured lungs, with therapeutic efficacy comparable to primary MSC-EVs.ConclusionsThis study establishes a scalable and standardized platform for producing high-quality iMSC-EVs using bioreactor-based systems. Our approach addresses key limitations in traditional EV production and sets the stage for AI-integrated, fully automated, GMP-compliant manufacturing of therapeutic EVs suitable for clinical translation.Supplementary InformationThe online version contains supplementary material available at 10.1186/s13287-025-04507-y.
Mesenchymal stem cell cryopreservation with cavitation-mediated trehalose treatment C. V. Fuenteslópez et al. Communications Engineering 2024 Sep

Abstract

Dimethylsulfoxide (DMSO) has conventionally been used for cell cryopreservation both in research and in clinical applications, but has long-term cytotoxic effects. Trehalose, a natural disaccharide, has been proposed as a non-toxic cryoprotectant. However, the lack of specific cell membrane transporter receptors inhibits transmembrane transport and severely limits its cryoprotective capability. This research presents a method to successfully deliver trehalose into mesenchymal stem cells (MSCs) using ultrasound in the presence of microbubbles. The optimised trehalose concentration was shown to be able to not only preserve membrane integrity and cell viability but also the multipotency of MSCs, which are essential for stem cell therapy. Confocal imaging revealed that rhodamine-labelled trehalose was transported into cells rather than simply attached to the membrane. Additionally, the membranes were successfully preserved in lyophilised cells. This study demonstrates that ultrasonication with microbubbles facilitated trehalose delivery, offering promising cryoprotective capability without the cytotoxicity associated with DMSO-based methods. Subject terms: Membrane biophysics, Biomedical engineering